SEMA4D and atypical Rett syndrome: The rapid response to the anti-SEMA4D antibody therapy in the symptomatic mice suggests anti-SEMA4D immunotherapy may have potential to treat the Rett syndrome girls who are usually diagnosed after symptom onset.